-
HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization
•
China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKSE). The proceeds from the IPO will be used for the manufacturing and commercialization of its COVID-19 therapy azvudine, as well as the clinical development of drugs for HIV infection,…
-
Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved
•
Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab),…
-
Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000 nasal spray, a Category 1 chemical drug targeting COVID-19, has been accepted for review by the National Medical Products Administration (NMPA). Drug DetailsHY3000 is a novel polypeptide membrane fusion inhibitor that binds to the HR1…
-
GenScript’s Legend Biotech Appoints Three New Directors to Board
•
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) has appointed Dr. Fangliang Zhang, Dr. Li Mao, and Mr. Tomas J. Heyman to the Company’s Board of Directors, effective as of August 2, 2022. Dr. Zhang, Dr. Mao, and…
-
Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta
•
The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant Boehringer Ingelheim (BI) in a patent infringement dispute with HEC and its affiliate Yichang HEC Changjiang Pharmaceutical Co., Ltd. The ruling centers on BI’s patent protecting the linagliptin compound used in its Trajenta diabetes drug.…
-
Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase IIb clinical trial (ZGJAK006) for its in-house Janus kinase (JAK) inhibitor, jacktinib, in patients with ruxolitinib-intolerant, medium- to high-risk myelofibrosis. The study met its primary endpoint, with 43.2% of subjects achieving ≥35% spleen volume reduction…
-
Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use
•
The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy image-assisted detection software for marketing in China. The software marks the country’s first deep learning – powered tool designed to aid in polyp detection during endoscopic procedures. Product FeaturesThe software integrates with specified electronic colonoscopes,…
-
Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use
•
The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm Ethicon LLC for its absorbable regenerated oxidized cellulose hemostatic granules, designated as an innovative product. The approval marks a milestone for Ethicon’s hemostatic portfolio in China’s surgical device market. Product DetailsThe approved product comprises two…
